SEC Form 4 · accession 0001209191-16-094287
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly Manhard
Officer — Executive VP, Drug Development
Period of report
Jan 28, 2016
Accepted (ET)
Jan 29, 2016 · 8:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818033
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $20.69 | Jan 28, 2016 | A | 300,000 | A | — | Jan 28, 2026 | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F1Options shall vest and become exercisable with respect to 75,000 shares on the first anniversary of her first day of employment (the "Grant Date"), followed by 225,000 shares vesting ratably each month over the subsequent three years, such that 300,000 options will be fully vested on the four-year anniversary of the Grant Date.